Pivotal roles of protein 4.1B/DAL‑1, a FERM‑domain containing protein, in tumor progression (Review)
Corrigendum in: /10.3892/ijo.2019.4935
- Authors:
- Xiaofeng Yuan
- Lianhua Piao
- Luhui Wang
- Xu Han
- Ming Zhuang
- Zhiwei Liu
-
Affiliations: Department of Orthopaedics, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu 213000, P.R. China, Institute of Bioinformatics and Medical Engineering, Jiangsu University of Technology, Changzhou, Jiangsu 213001, P.R. China, Department of Urology, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu 213000, P.R. China - Published online on: September 13, 2019 https://doi.org/10.3892/ijo.2019.4877
- Pages: 979-987
This article is mentioned in:
Abstract
Cifuentes-Diaz C, Chareyre F, Garcia M, Devaux J, Carnaud M, Levasseur G, Niwa-Kawakita M, Harroch S, Girault JA, Giovannini M and Goutebroze L: Protein 4.1B contributes to the organization of peripheral myelinated axons. PLoS One. 6:e250432011. View Article : Google Scholar : PubMed/NCBI | |
Hoover KB and Bryant PJ: The genetics of the protein 4.1 family: Organizers of the membrane and cytoskeleton. Curr Opin Cell Biol. 12:229–234. 2000. View Article : Google Scholar : PubMed/NCBI | |
Diakowski W, Grzybek M and Sikorski AF: Protein 4.1, a component of the erythrocyte membrane skeleton and its related homologue proteins forming the protein 4.1/FERM superfamily. Folia Histochem Cytobiol. 44:231–248. 2006. | |
Takeuchi K, Kawashima A, Nagafuchi A and Tsukita S: Structural diversity of band 4.1 superfamily members. J Cell Sci. 107:1921–1928. 1994.PubMed/NCBI | |
Sun CX, Robb VA and Gutmann DH: Protein 4.1 tumor suppressors: Getting a FERM grip on growth regulation. J Cell Sci. 115:3991–4000. 2002. View Article : Google Scholar : PubMed/NCBI | |
Chishti AH, Kim AC, Marfatia SM, Lutchman M, Hanspal M, Jindal H, Liu SC, Low PS, Rouleau GA, Mohandas N, et al: The FERM domain: A unique module involved in the linkage of cytoplasmic proteins to the membrane. Trends Biochem Sci. 23:281–282. 1998. View Article : Google Scholar : PubMed/NCBI | |
Parra M, Gee S, Chan N, Ryaboy D, Dubchak I, Mohandas N, Gascard PD and Conboy JG: Differential domain evolution and complex RNA processing in a family of paralogous EPB41 (protein 4.1) genes facilitate expression of diverse tissue-specific isoforms. Genomics. 84:637–646. 2004. View Article : Google Scholar : PubMed/NCBI | |
Tran YK, Bögler O, Gorse KM, Wieland I, Green MR and Newsham IF: A novel member of the NF2/ERM/4.1 superfamily with growth suppressing properties in lung cancer. Cancer Res. 59:35–43. 1999.PubMed/NCBI | |
Kikuchi S, Yamada D, Fukami T, Masuda M, Sakurai-Yageta M, Williams YN, Maruyama T, Asamura H, Matsuno Y, Onizuka M and Murakami Y: Promoter methylation of DAL-1/4.1B predicts poor prognosis in non-small cell lung cancer. Clin Cancer Res. 11:2954–2961. 2005. View Article : Google Scholar : PubMed/NCBI | |
Liang H, Yan X, Pan Y, Wang Y, Wang N, Li L, Liu Y, Chen X, Zhang CY, Gu H and Zen K: MicroRNA-223 delivered by platelet-derived microvesicles promotes lung cancer cell invasion via targeting tumor suppressor EPB41L3. Mol Cancer. 14:582015. View Article : Google Scholar : PubMed/NCBI | |
Yageta M, Kuramochi M, Masuda M, Fukami T, Fukuhara H, Maruyama T, Shibuya M and Murakami Y: Direct association of TSLC1 and DAL-1, two distinct tumor suppressor proteins in lung cancer. Cancer Res. 62:5129–5133. 2002.PubMed/NCBI | |
Gutmann DH, Donahoe J, Perry A, Lemke N, Gorse K, Kittiniyom K, Rempel SA, Gutierrez JA and Newsham IF: Loss of DAL-1, a protein 4.1-related tumor suppressor, is an important early event in the pathogenesis of meningiomas. Hum Mol Genet. 9:1495–1500. 2000. View Article : Google Scholar : PubMed/NCBI | |
Tran Y, Benbatoul K, Gorse K, Rempel S, Futreal A, Green M and Newsham I: Novel regions of allelic deletion on chromosome 18p in tumors of the lung, brain and breast. Oncogene. 17:3499–3505. 1998. View Article : Google Scholar | |
Nunes F, Shen Y, Niida Y, Beauchamp R, Stemmer- Rachamimov AO, Ramesh V, Gusella J and MacCollin M: Inactivation patterns of NF2 and DAL-1/4.1B (EPB41L3) in sporadic meningioma. Cancer Genet Cytogenet. 162:135–139. 2005. View Article : Google Scholar : PubMed/NCBI | |
Robb VA, Gerber MA, Hart-Mahon EK and Gutmann DH: Membrane localization of the U2 domain of Protein 4.1B is necessary and sufficient for meningioma growth suppression. Oncogene. 24:1946–1957. 2005. View Article : Google Scholar : PubMed/NCBI | |
Gerber MA, Bahr SM and Gutmann DH: Protein 4.1B/differentially expressed in adenocarcinoma of the lung-1 functions as a growth suppressor in meningioma cells by activating Rac1-dependent c-Jun-NH(2)-kinase signaling. Cancer Res. 66:5295–5303. 2006. View Article : Google Scholar : PubMed/NCBI | |
Kittiniyom K, Mastronardi M, Roemer M, Wells WA, Greenberg ER, Titus-Ernstoff L and Newsham IF: Allele-specific loss of heterozygosity at the DAL-1/4.1B (EPB41L3) tumor-suppressor gene locus in the absence of mutation. Genes Chromosomes Cancer. 40:190–203. 2004. View Article : Google Scholar : PubMed/NCBI | |
Kittiniyom K, Gorse KM, Dalbegue F, Lichy JH, Taubenberger JK and Newsham IF: Allelic loss on chromosome band 18p11.3 occurs early and reveals heterogeneity in breast cancer progression. Breast Cancer Res. 3:192–198. 2001. View Article : Google Scholar : PubMed/NCBI | |
Dafou D, Grun B, Sinclair J, Lawrenson K, Benjamin EC, Hogdall E, Kruger-Kjaer S, Christensen L, Sowter HM, Al-Attar A, et al: Microcell-mediated chromosome transfer identifies EPB41L3 as a functional suppressor of epithelial ovarian cancers. Neoplasia. 12:579–589. 2010. View Article : Google Scholar : PubMed/NCBI | |
Bernkopf DB and Williams ED: Potential role of EPB41L3 (protein 4.1B/Dal-1) as a target for treatment of advanced prostate cancer. Expert Opin Ther Targets. 12:845–853. 2008. View Article : Google Scholar : PubMed/NCBI | |
Wong SY, Haack H, Kissil JL, Barry M, Bronson RT, Shen SS, Whittaker CA, Crowley D and Hynes RO: Protein 4.1B suppresses prostate cancer progression and metastasis. Proc Natl Acad Sci USA. 104:12784–12789. 2007. View Article : Google Scholar : PubMed/NCBI | |
Wang Z, Zhang J, Ye M, Zhu M, Zhang B, Roy M, Liu J and An X: Tumor suppressor role of protein 4.1B/DAL-1. Cell Mol Life Sci. 71:4815–4830. 2014. View Article : Google Scholar : PubMed/NCBI | |
Holzwarth G, Yu J and Steck TL: Heterogeneity in the conformation of different protein fractions from the human erythrocyte membrane. J Supramol Struct. 4:161–168. 1976. View Article : Google Scholar : PubMed/NCBI | |
Parra M, Gascard P, Walensky LD, Gimm JA, Blackshaw S, Chan N, Takakuwa Y, Berger T, Lee G, Chasis JA, et al: Molecular and functional characterization of protein 4.1B, a novel member of the protein 4.1 family with high level, focal expression in brain. J Biol Chem. 275:3247–3255. 2000. View Article : Google Scholar : PubMed/NCBI | |
Leto TL and Marchesi VT: A structural model of human erythrocyte protein 4.1. J Biol Chem. 259:4603–4608. 1984.PubMed/NCBI | |
Busam RD, Thorsell AG, Flores A, Hammarström M, Persson C, Öbrink B and Hallberg BM: Structural basis of tumor suppressor in lung cancer 1 (TSLC1) binding to differentially expressed in adenocarcinoma of the lung (DAL-1/4.1B). J Biol Chem. 286:4511–4516. 2011. View Article : Google Scholar : | |
Nagata M, Sakurai-Yageta M, Yamada D, Goto A, Ito A, Fukuhara H, Kume H, Morikawa T, Fukayama M, Homma Y and Murakami Y: Aberrations of a cell adhesion molecule CADM4 in renal clear cell carcinoma. Int J Cancer. 130:1329–1337. 2012. View Article : Google Scholar | |
Sakurai-Yageta M, Masuda M, Tsuboi Y, Ito A and Murakami Y: Tumor suppressor CADM1 is involved in epithelial cell structure. Biochem Biophys Res Commun. 390:977–982. 2009. View Article : Google Scholar : PubMed/NCBI | |
Singh V, Miranda TB, Jiang W, Frankel A, Roemer ME, Robb VA, Gutmann DH, Herschman HR, Clarke S and Newsham IF: DAL-1/4.1B tumor suppressor interacts with protein arginine N-methyltransferase 3 (PRMT3) and inhibits its ability to methylate substrates in vitro and in vivo. Oncogene. 23:7761–7771. 2004. View Article : Google Scholar : PubMed/NCBI | |
Jiang W, Roemer ME and Newsham IF: The tumor suppressor DAL-1/4.1B modulates protein arginine N-methyltransferase 5 activity in a substrate-specific manner. Biochem Biophys Res Commun. 329:522–530. 2005. View Article : Google Scholar : PubMed/NCBI | |
Horresh I, Bar V, Kissil JL and Peles E: Organization of myelinated axons by Caspr and Caspr2 requires the cytoskeletal adapter protein 4.1B. J Neurosci. 30:2480–2489. 2010. View Article : Google Scholar : PubMed/NCBI | |
Yu T, Robb VA, Singh V, Gutmann DH and Newsham IF: The 4.1/ezrin/radixin/moesin domain of the DAL-1/Protein 4.1B tumour suppressor interacts with 14-3-3 proteins. Biochem J. 365:783–789. 2002. View Article : Google Scholar : PubMed/NCBI | |
Gimm JA, An X, Nunomura W and Mohandas N: Functional characterization of spectrin-actin-binding domains in 4.1 family of proteins. Biochemistry. 41:7275–7282. 2002. View Article : Google Scholar : PubMed/NCBI | |
Discher DE, Winardi R, Schischmanoff PO, Parra M, Conboy JG and Mohandas N: Mechanochemistry of protein 4.1's spectrin-actin-binding domain: Ternary complex interactions, membrane binding, network integration, structural strengthening. J Cell Biol. 130:897–907. 1995. View Article : Google Scholar : PubMed/NCBI | |
Discher D, Parra M, Conboy JG and Mohandas N: Mechanochemistry of the alternatively spliced spectrin-actin binding domain in membrane skeletal protein 4.1. J Biol Chem. 268:7186–7195. 1993.PubMed/NCBI | |
Kontrogianni-Konstantopoulos A, Huang SC and Benz EJ Jr: A nonerythroid isoform of protein 4.1R interacts with components of the contractile apparatus in skeletal myofibers. Mol Biol Cell. 11:3805–3817. 2000. View Article : Google Scholar : PubMed/NCBI | |
McCarty JH, Cook AA and Hynes RO: An interaction between {alpha}v{beta}8 integrin and Band 4.1B via a highly conserved region of the Band 4.1 C-terminal domain. Proc Natl Acad Sci USA. 102:13479–13483. 2005. View Article : Google Scholar : PubMed/NCBI | |
Zhang Y, Xu R, Li G, Xie X, Long J and Wang H: Loss of expression of the differentially expressed in adenocarcinoma of the lung (DAL-1) protein is associated with metastasis of non-small cell lung carcinoma cells. Tumour Biol. 33:1915–1925. 2012. View Article : Google Scholar : PubMed/NCBI | |
Charboneau AL, Singh V, Yu T and Newsham IF: Suppression of growth and increased cellular attachment after expression of DAL-1 in MCF-7 breast cancer cells. Int J Cancer. 100:181–188. 2002. View Article : Google Scholar : PubMed/NCBI | |
Qiu X, Guan X, Liu W and Zhang Y: DAL-1 attenuates epithelial to mesenchymal transition and metastasis by suppressing HSPA5 expression in non-small cell lung cancer. Oncol Rep. 38:3103–3113. 2017. View Article : Google Scholar : PubMed/NCBI | |
Chen X, Guan X, Zhang H, Xie X, Wang H, Long J, Cai T, Li S, Liu Z and Zhang Y: DAL-1 attenuates epithelial-to mesenchymal transition in lung cancer. J Exp Clin Cancer Res. 34:32015. View Article : Google Scholar : PubMed/NCBI | |
Yu F, Yang H, Zhang Z, Wang Z and Xiong J: DAL-1/4.1B contributes to epithelial-mesenchymal transition via regulation of transforming growth factor-β in lung cancer cell lines. Mol Med Rep. 12:6072–6078. 2015. View Article : Google Scholar : PubMed/NCBI | |
Heller G, Fong KM, Girard L, Seidl S, End-Pfützenreuter A, Lang G, Gazdar AF, Minna JD, Zielinski CC and Zöchbauer-Müller S: Expression and methylation pattern of TSLC1 cascade genes in lung carcinomas. Oncogene. 25:959–968. 2006. View Article : Google Scholar | |
Martín-Sánchez E, Pernaut-Leza E, Mendaza S, Cordoba A, Vicente-Garcia F, Monreal-Santesteban I, Vizcaino JP, De Cerio MJ, Perez-Janices N, Blanco-Luquin I, et al: Gene promoter hypermethylation is found in sentinel lymph nodes of breast cancer patients, in samples identified as positive by one-step nucleic acid amplification of cytokeratin 19 mRNA. Virchows Arch. 469:51–59. 2016. View Article : Google Scholar : PubMed/NCBI | |
Jiang W and Newsham IF: The tumor suppressor DAL-1/4.1B and protein methylation cooperate in inducing apoptosis in MCF-7 breast cancer cells. Mol Cancer. 5:42006. View Article : Google Scholar : PubMed/NCBI | |
Schulz WA, Alexa A, Jung V, Hader C, Hoffmann MJ, Yamanaka M, Fritzsche S, Wlazlinski A, Müller M, Lengauer T, et al: Factor interaction analysis for chromosome 8 and DNA methylation alterations highlights innate immune response suppression and cytoskeletal changes in prostate cancer. Mol Cancer. 6:142007. View Article : Google Scholar : PubMed/NCBI | |
Schulz WA, Ingenwerth M, Djuidje CE, Hader C, Rahnenführer J and Engers R: Changes in cortical cytoskeletal and extracellular matrix gene expression in prostate cancer are related to oncogenic ERG deregulation. BMC Cancer. 10:5052010. View Article : Google Scholar : PubMed/NCBI | |
Vasiljević N, Ahmad AS, Carter PD, Fisher G, Berney DM, Foster CS, Cuzick J and Lorincz AT: DNA methylation of PITX2 predicts poor survival in men with prostate cancer. Biomark Med. 8:1143–1150. 2014. View Article : Google Scholar | |
Schulz WA and Hoffmann MJ: Epigenetic mechanisms in the biology of prostate cancer. Semin Cancer Biol. 19:172–180. 2009. View Article : Google Scholar : PubMed/NCBI | |
Li X, Zhou F, Jiang C, Wang Y, Lu Y, Yang F, Wang N, Yang H, Zheng Y and Zhang J: Identification of a DNA methylome profile of esophageal squamous cell carcinoma and potential plasma epigenetic biomarkers for early diagnosis. PLoS One. 9:e1031622014. View Article : Google Scholar : PubMed/NCBI | |
Maher SG, Gillham CM, Duggan SP, Smyth PC, Miller N, Muldoon C, O'Byrne KJ, Sheils OM, Hollywood D and Reynolds JV: Gene expression analysis of diagnostic biopsies predicts pathological response to neoadjuvant chemoradiotherapy of esophageal cancer. Ann Surg. 250:729–737. 2009. View Article : Google Scholar : PubMed/NCBI | |
Zeng R, Huang JP, Li XF, Xiong WB, Wu G, Jiang ZJ, Song SJ, Li JQ, Zheng YF and Zhang JR: Epb41l3 suppresses esophageal squamous cell carcinoma invasion and inhibits MMP2 and MMP9 expression. Cell Biochem Funct. 34:133–141. 2016. View Article : Google Scholar : PubMed/NCBI | |
Zeng R, Liu Y, Jiang ZJ, Huang JP, Wang Y, Li XF, Xiong WB, Wu XC, Zhang JR, Wang QE and Zheng YF: EPB41L3 is a potential tumor suppressor gene and prognostic indicator in esophageal squamous cell carcinoma. Int J Oncol. Mar 14–2018.Epub ahead of print. | |
Verlaat W, Van Leeuwen RW, Novianti PW, Schuuring E, Meijer CJLM, Van Der Zee AGJ, Snijders PJF, Heideman DAM, Steenbergen RDM and Wisman GBA: Host-cell DNA methylation patterns during high-risk HPV-induced carcinogenesis reveal a heterogeneous nature of cervical pre-cancer. Epigenetics. 13:769–778. 2018. View Article : Google Scholar : PubMed/NCBI | |
Vasiljević N, Scibior-Bentkowska D, Brentnall AR, Cuzick J and Lorincz AT: Credentialing of DNA methylation assays for human genes as diagnostic biomarkers of cervical intraepithelial neoplasia in high-risk HPV positive women. Gynecol Oncol. 132:709–714. 2014. View Article : Google Scholar | |
Brentnall AR, Vasiljević N, Scibior-Bentkowska D, Cadman L, Austin J, Szarewski A, Cuzick J and Lorincz AT: A DNA methylation classifier of cervical precancer based on human papillomavirus and human genes. Int J Cancer. 135:1425–1432. 2014. View Article : Google Scholar : PubMed/NCBI | |
Boers A, Wang R, van Leeuwen RW, Klip HG, de Bock GH, Hollema H, van Criekinge W, de Meyer T, Denil S, van der Zee AGJ, et al: Discovery of new methylation markers to improve screening for cervical intraepithelial neoplasia grade 2/3. Clin Epigenetics. 8:292016. View Article : Google Scholar : PubMed/NCBI | |
Louvanto K, Franco EL, Ramanakumar AV, Vasiljević N, Scibior-Bentkowska D, Koushik A, Cuzick J, Coutlée F and Lorincz AT; Biomarkers of Cervical Cancer Risk Study Team: Methylation of viral and host genes and severity of cervical lesions associated with human papillomavirus type 16. Int J Cancer. 136:E638–E645. 2015. View Article : Google Scholar | |
Kelly HA, Chikandiwa A, Warman R, Segondy M, Sawadogo B, Vasiljević N, Didelot MN, Meda N, Weiss HA, Delany-Moretlwe S, et al: Associations of human gene EPB41L3 DNA methylation and cervical intraepithelial neoplasia in women living with HIV-1 in Africa. AIDS. 32:2227–2236. 2018. View Article : Google Scholar : PubMed/NCBI | |
Clarke MA, Luhn P, Gage JC, Bodelon C, Dunn ST, Walker J, Zuna R, Hewitt S, Killian JK, Yan L, et al: Discovery and validation of candidate host DNA methylation markers for detection of cervical precancer and cancer. Int J Cancer. 141:701–710. 2017. View Article : Google Scholar : PubMed/NCBI | |
Cuschieri K, Ronco G, Lorincz A, Smith L, Ogilvie G, Mirabello L, Carozzi F, Cubie H, Wentzensen N, Snijders P, et al: Eurogin roadmap 2017: Triage strategies for the management of HPV-positive women in cervical screening programs. Int J Cancer. 143:735–745. 2018. View Article : Google Scholar : PubMed/NCBI | |
Lorincz AT, Brentnall AR, Scibior-Bentkowska D, Reuter C, Banwait R, Cadman L, Austin J, Cuzick J and Vasiljević N: Validation of a DNA methylation HPV triage classifier in a screening sample. Int J Cancer. 138:2745–2751. 2016. View Article : Google Scholar : PubMed/NCBI | |
Nedjai B, Reuter C, Ahmad A, Banwait R, Warman R, Carton J, Boer S, Cuzick J and Lorincz AT: Molecular progression to cervical precancer, epigenetic switch or sequential model? Int J Cancer. Apr 21–2018.Epub ahead of print. View Article : Google Scholar : PubMed/NCBI | |
Huisman C, van der Wijst MG, Falahi F, Overkamp J, Karsten G, Terpstra MM, Kok K, van der Zee AG, Schuuring E, Wisman GB and Rots MG: Prolonged re-expression of the hypermethylated gene EPB41L3 using artificial transcription factors and epigenetic drugs. Epigenetics. 10:384–396. 2015. View Article : Google Scholar : PubMed/NCBI | |
Brentnall AR, Vasiljević N, Scibior-Bentkowska D, Cadman L, Austin J, Cuzick J and Lorincz AT: HPV33 DNA methylation measurement improves cervical pre-cancer risk estimation of an HPV16, HPV18, HPV31 and \textit{EPB41L3} methylation classifier. Cancer Biomark. 15:669–675. 2015. View Article : Google Scholar : PubMed/NCBI | |
Lorincz AT: Virtues and weaknesses of DNA methylation as a test for cervical cancer prevention. Acta Cytol. 60:501–512. 2016. View Article : Google Scholar : PubMed/NCBI | |
van Leeuwen RW, Ostrbenk A, Poljak M, van der Zee AGJ, Schuuring E and Wisman GBA: DNA methylation markers as a triage test for identification of cervical lesions in a high risk human papillomavirus positive screening cohort. Int J Cancer. 144:746–754. 2019. View Article : Google Scholar : | |
Eijsink JJ, Lendvai Á, Deregowski V, Klip HG, Verpooten G, Dehaspe L, de Bock GH, Hollema H, van Criekinge W, Schuuring E, et al: A four-gene methylation marker panel as triage test in high-risk human papillomavirus positive patients. Int J Cancer. 130:1861–1869. 2012. View Article : Google Scholar | |
Lendvai Á, Johannes F, Grimm C, Eijsink JJ, Wardenaar R, Volders HH, Klip HG, Hollema H, Jansen RC, Schuuring E, et al: Genome-wide methylation profiling identifies hypermethylated biomarkers in high-grade cervical intraepithelial neoplasia. Epigenetics. 7:1268–1278. 2012. View Article : Google Scholar : PubMed/NCBI | |
Perez-Janices N, Blanco-Luquin I, Tuñón MT, Barba-Ramos E, Ibáñez B, Zazpe-Cenoz I, Martinez-Aguillo M, Hernandez B, Martínez-Lopez E, Fernández AF, et al: EPB41L3, TSP-1 and RASSF2 as new clinically relevant prognostic biomarkers in diffuse gliomas. Oncotarget. 6:368–380. 2015. View Article : Google Scholar : PubMed/NCBI | |
Ohno N, Terada N, Murata S, Yamakawa H, Newsham IF, Katoh R, Ohara O and Ohno S: Immunolocalization of protein 4.1B/DAL-1 during neoplastic transformation of mouse and human intestinal epithelium. Histochem Cell Biol. 122:579–586. 2004. View Article : Google Scholar : PubMed/NCBI | |
Kume H, Muraoka S, Kuga T, Adachi J, Narumi R, Watanabe S, Kuwano M, Kodera Y, Matsushita K, Fukuoka J, et al: Discovery of colorectal cancer biomarker candidates by membrane proteomic analysis and subsequent verification using selected reaction monitoring (SRM) and tissue microarray (TMA) analysis. Mol Cell Proteomics. 13:1471–1484. 2014. View Article : Google Scholar : PubMed/NCBI | |
Niwa T, Tsukamoto T, Toyoda T, Mori A, Tanaka H, Maekita T, Ichinose M, Tatematsu M and Ushijima T: Inflammatory processes triggered by Helicobacter pylori infection cause aberrant DNA methylation in gastric epithelial cells. Cancer Res. 70:1430–1440. 2010. View Article : Google Scholar : PubMed/NCBI | |
Sugimoto K, Ito T, Hulbert A, Chen C, Orita H, Maeda M, Moro H, Fukagawa T, Ushijima T, Katai H, et al: DNA methylation genome-wide analysis in remnant and primary gastric cancers. Gastric Cancer. Mar 12–2019. View Article : Google Scholar : Epub ahead of print. View Article : Google Scholar : PubMed/NCBI | |
Terada N, Ohno N, Yamakawa H, Baba T, Fujii Y, Christofori G, Ohara O and Ohno S: Protein 4.1B in mouse islets of Langerhans and beta-cell tumorigenesis. Histochem Cell Biol. 120:277–283. 2003. View Article : Google Scholar : PubMed/NCBI | |
Zhu L, Yang N, Chen J, Zeng T, Yan S, Liu Y, Yu G, Chen Q, Du G, Pan W, et al: LINC00052 upregulates EPB41L3 to inhibit migration and invasion of hepatocellular carcinoma by binding miR-452-5p. Oncotarget. 8:63724–63737. 2017.PubMed/NCBI | |
Giuliano AR, Nedjai B, Lorincz AT, Schell MJ, Rahman S, Banwait R, Boulware D, Sirak B, Martin-Gomez L, Abrahamsen M, et al: Methylation of HPV 16 and EPB41L3 in oral gargles: Associations with oropharyngeal cancer detection and tumor characteristics. Int J Cancer. Jul 15–2019.Epub ahead of print. View Article : Google Scholar : PubMed/NCBI | |
Lorincz AT, Nathan M, Reuter C, Warman R, Thaha MA, Sheaff M, Vasiljević N, Ahmad A, Cuzick J and Sasieni P: Methylation of HPV and a tumor suppressor gene reveals anal cancer and precursor lesions. Oncotarget. 8:50510–50520. 2017. View Article : Google Scholar : PubMed/NCBI | |
Yamada D, Kikuchi S, Williams YN, Sakurai-Yageta M, Masuda M, Maruyama T, Tomita K, Gutmann DH, Kakizoe T, Kitamura T, et al: Promoter hypermethylation of the potential tumor suppressor DAL-1/4.1B gene in renal clear cell carcinoma. Int J Cancer. 118:916–923. 2006. View Article : Google Scholar | |
Jiang SS, Chen CH, Tseng KY, Tsai FY, Wang MJ, Chang IS, Lin JL and Lin S: Gene expression profiling suggests a pathological role of human bone marrow-derived mesenchymal stem cells in aging-related skeletal diseases. Aging (Albany NY). 3:672–684. 2011. View Article : Google Scholar | |
Heller G, Geradts J, Ziegler B, Newsham I, Filipits M, Markis-Ritzinger EM, Kandioler D, Berger W, Stiglbauer W, Depisch D, et al: Downregulation of TSLC1 and DAL-1 expression occurs frequently in breast cancer. Breast Cancer Res Treat. 103:283–291. 2007. View Article : Google Scholar : PubMed/NCBI | |
Li L, Li S, Cai T, Wang H, Xie X, Liu Z and Zhang Y: The targeted inhibitory effects of human amniotic fluid stem cells carrying CXCR4 promoter and DAL-1 on non-small cell lung carcinoma growth. Gene Ther. 23:214–222. 2016. View Article : Google Scholar |